drugset / Trial / NCT07267299

Switching From Restasis to TRYPTYR

NCT07267299 ↗

Phase 4 Not yet recruiting 100 enrolled Southern College of Optometry
NaSingle-groupOpen-labelTreatment

Summary

Switching to acoltremon 0.003% will significantly improve the signs and symptoms of participants who were being treated with Restasis at 28 days post-treatment compared to baseline. Dry eye disease (DED) is a prevalent condition that commonly affects patients of working age in addition to the elderly. DED is a complex condition that results in ocular symptoms such as dryness and burning and signs such as decreased tear production (aqueous deficient DED) or increased tear evaporation (evaporative DED). Unfortunately, there is not a perfect correlation between DED signs and symptoms, which makes diagnosis and timely treatment challenging.

Timeline

Start
2025-12-01
Primary completion
2026-04-01
Completion
2026-05-15

Drugs

EvaluationDrugModalityDoseRoute
Subject Acoltremon Small molecule 0.003 % —

Indications